Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Johan Sebastian Lopez-Parra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomaterials and Biomedical Technology. The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (…. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 102 Literaturangaben. Gefördert von: HORIZON EUROPE European Innovation Council, Universitair Medisch Centrum Groningen, H2020 Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
Therapeutic resistance in glioblastoma (GBM) remains a critical clinical challenge. To better understand its molecular basis, we performed a multistage computational analysis on a resistant GBM data set derived from the Ivy Glioblastoma Atlas Project, filtered for unmethylated MGMT and EGFR amplification. A subtype-specificity analysis identified distinct expression patterns for established biomarkers, including PDGFRA, FAP, and CD163, providing refined context for their roles in specific GBM subtypes. Kaplan-Meier analysis confirmed that high PDGFRA expression correlates with poor survival in this resistant population. To explore its therapeutic tractability, we developed a Quantitative Structure-Activity Relationship (QSAR) model targeting PDGFRA. This led to the in silico identification of a novel lead compound with a distinct thiazolopyridine-based scaffold and high predicted potency. Our findings demonstrate how integrated bioinformatic pipelines can dissect the complex landscape of GBM resistance, contextualize the roles of key oncogenes, and guide the rational design of potential new inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomaterials and Biomedical Technology. The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen,…
- Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
- LAQV/REQUIMTE─BioSIM, Departamento de Biomedicina, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.
- Departamento de Engenharia Química, Faculdade de Ciências e de Tecnologia, Universidade de Coimbra, 3001-401 Coimbra, Portugal.
- Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
ORCID-Profile: Sérgio F Sousa, Flávia Sousa, Hélder A Santos
Förderung
- HORIZON EUROPE European Innovation Council
- Universitair Medisch Centrum Groningen
- H2020 Marie Sklodowska-Curie Actions
- Health-Holland
Zitieren
APA
Lopez-Parra, J. S., Hameedat, F., Sousa, S. F., Walenkamp, A. M. E., Sousa, F., & A Santos, H. (2026). Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01538
Vancouver
Lopez-Parra JS, Hameedat F, Sousa SF, Walenkamp AME, Sousa F, A Santos H. Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01538
BibTeX
@article{LopezParra2026,
author = {Lopez-Parra, Johan Sebastian and Hameedat, Fatima and Sousa, Sérgio F and Walenkamp, Annemiek M E and Sousa, Flávia and A Santos, Hélder},
title = {Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01538}
}
EUVIMED